Shares of Kamada Ltd. (NASDAQ:KMDA) were up 1.9% during trading on Wednesday . The company traded as high as $4.20 and last traded at $4.20, with a volume of 67,520 shares traded. The stock had previously closed at $4.12.

KMDA has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Kamada from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Thursday, August 4th. TheStreet upgraded Kamada from a “sell” rating to a “hold” rating in a report on Monday, April 25th.

The firm has a 50-day moving average price of $3.94 and a 200-day moving average price of $3.84. The firm’s market cap is $152.96 million.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). The firm earned $19.10 million during the quarter, compared to the consensus estimate of $18.50 million. On average, equities research analysts anticipate that Kamada Ltd. will post ($0.11) earnings per share for the current fiscal year.

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.